Patrick is a Partner in the Innovation department. He is Co-Head for Commercial, Technology, Data and Sport within the Innovation Department and Head of the Life Sciences Group.
He is nationally recognised leading IP lawyer specialising in the life sciences sector. He looks after technology businesses’ commercial needs, and loves getting IP deals done. He has developed a detailed knowledge of the interface between the public and private sector and works extensively with high growth entrepreneurial businesses.
Throughout his career, Patrick has specialised in IP matters and technology (in particular patents and know-how), always with a focus on the life sciences sector. He has experience in advising on:
- IP licences
- R&D agreements
- Joint ventures
- Spin-outs and start-ups
- Regulatory issues
- IP strategy
- Strategic partnerships
Patrick is regularly endorsed as a leading IP lawyer in Legal 500, Chambers and PLC’s Which Lawyer (Life Sciences) Guide. He is also a Chair of the University of Cambridge’s Technology Appeals Tribunal. He is a dual UK and Swiss national and fluent French speaker.
- Microbiotica: advising on its strategic collaboration with Genentech for microbiome biomarker signatures and therapeutic discovery, based on Genentech’s inflammatory bowel disease pipeline and utilising Microbiotica’s leading gut microbiome Reference Genome Database and Culture Collection. Microbiotica to receive up to $534 million in upfront and milestone payments.
- RQ Bio: advising on its $157m licence with AstraZeneca to help progress the treatment and prevention of viruses through antibody technologies. Supporting them with two previous funding rounds and in securing licensing agreements with Oxford University Innovation and AstraZeneca means that significant progress is being made in protecting vulnerable patients against COVID 19.
- DIOSynVax: advising on its $42m deal with CEPI, announced at the Global Pandemic Preparedness Summit in Oslo, Norway. This funding from CEPI (the Coalition for Epidemic Preparedness Innovations) will support in developing a vaccine that could provide protection against both existing and future variants of SARS CoV 2 the virus which causes COVID 19 disease as well as other Betacoronaviruses including those which cause SARS and MERS.
- University of Bristol: advising on the IP licence for its kidney gene therapy spin out Purespring. We helped on all aspects of the IP licence as well as helping them close the £45m funding deal with Syncona. Syncona had specific requirements that resulted in some very complex IP licensing negotiations.
- Adaptate: advising on all IP aspects of its spin out from GammaDelta Therapeutics, backed by Abingworth and Takeda and its subsequent sale to Takeda. Adaptate developed technology to modulate γδ T cell activity using therapeutic antibodies, with the potential to trigger an immune response against cancer.
Partner, Mishcon de Reya LLP
Partner, Taylor Vinters LLP
University Of London, LLB Law